

STIC-ILL

STIC

From: Andres, Janet
Sent: Tuesday, April 18, 2000 2:42 PM
To: STIC-ILL
Subject: 09/386591

Name: Janet Andres
AU: 1642
phone: 305-0557
office: 8A13
serial number 09386591

Please send me:

Clarke B E; Newton S E; Carroll A R; Francis M J; Appleyard G; Syred A D; Highfield P E; Rowlands D J; Brown F. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. NATURE. (1987 Nov 26-Dec 2) 330 (6146) 381-4.

Francis M J; Clarke B E. Peptide vaccines based on enhanced immunogenicity of peptide epitopes presented with T-cell determinants or hepatitis B core protein. METHODS IN ENZYMOLOGY. (1989) 178 659-76.

Beesley K M; Francis M J; Clarke B E; Beesley J E. Expression in yeast of amino-terminal peptide fusions to hepatitis B core antigen and their immunological properties. BIO/TECHNOLOGY. (1990 Jul) 8 (7) 644-9.

Charles I G; Li J L; Roberts M; Beesley K; Romanos M; Pickard D J; Francis M; Campbell D; Dougan G; Brennan M J et al. Identification and characterization of a protective immunodominant B cell epitope of pertactin (P.69) from Bordetella pertussis. EUROPEAN JOURNAL OF IMMUNOLOGY. (1991 May) 21 (5) 1147-53.

Thanks.

EXPRESSION IN YEAST OF AMINO-TERMINAL PEPTIDE FUSIONS TO HEPATITIS B CORE ANTIGEN AND THEIR IMMUNOLOGICAL PROPERTIES

K. M. Beesley, M. J. Francis¹, B. E. Clarke¹, J. E. Beesley², P. J. C. Dopping-Hepenstal², J. J. Clare, F. Brown¹ and M. A. Romanos*

Departments of Molecular Biology and Virology¹, Wellcome Biotech, and Microscopy Unit, (Pharmacology)², Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS. *Corresponding author.

Hepatitis B core protein (HBcAg) is a potent antigen that gives both a T-cell-dependent and a T-cell-independent antibody response. It has been shown that a foreign epitope can be fused to the amino terminus of HBcAg without affecting particle integrity, and that the resulting chimaeric cores retain the immunogenicity of the foreign epitope. Here we describe the efficient expression in yeast of two different chimaeric cores, carrying epitopes of Foot and Mouth Disease Virus (FMDV) or human chorionic gonadotrophin (hCG), which are candidates for FMD and contraceptive vaccines, respectively. These cores could not be produced in *E. coli* in soluble form but were expressed to high levels in yeast. We constructed a yeast expression vector that allows rapid production of different chimaeric cores by cloning in cassettes encoding foreign epitopes. Both FMDV and hCG-cores were shown to present the epitopes at the surface of the particles. The FMDV-cores produced in yeast were efficient inducers of neutralising antibodies in guinea-pigs after one low dose.

Hepatitis B core antigen (HBcAg), which encapsidates the genome of hepatitis B virus (HBV), is a 21kD protein able to self-assemble into 27nm core particles when expressed in foreign host cells^{1,2}. The gene encoding HBcAg is unusual in that it gives rise to two related polypeptides HBcAg and hepatitis B e antigen (HBeAg), depending on which of two initiation codons is used³. Initiation at an upstream ATG leads to translation of 'pre-core' sequences encoding a signal peptide. Cleavage of the signal peptide and the C-terminal protamine-like region of pre-HBeAg gives rise to the mature, secreted HBeAg (17kDa). Alternatively, use of the downstream ATG produces the 21kD HBcAg. Expression in *E. coli* and yeast of HBcAg DNA containing 'pre-core' sequences indicated that HBcAg containing N-terminal extensions would still form particles (P. E. Highfield, pers. comm. and ref. 2).

HBcAg particles are exceptionally potent antigens, having both a T-cell-dependent and a T-cell-independent response⁴. This property is probably due to their multivalent particulate nature and to the presence of several

efficient helper T-cell epitopes in the polypeptide. Given their ability to form chimaeric particles carrying N-terminal extensions, they have been proposed as a general carrier vehicle for the presentation of epitopes in the development of subunit vaccines. This type of approach for polyvalent antigen presentation was first described by Valenzuela and co-workers⁵ who fused a portion of the herpes simplex virus glycoprotein D to the N-terminus of hepatitis B surface antigen. Another example is the use of yeast transposon virus-like particles⁶ (TyVLPs).

The first example of the use of HBcAg as a carrier was with the major immunogenic epitope of FMDV, the 142–160 peptide of the capsid protein VP1. A chimaeric particle containing this peptide has been shown to be a potent immunogen, giving rise to protective antibodies in guinea-pigs when injected once in low doses⁷. Several other N-terminal HBcAg fusions, produced using an *E. coli* expression system, are also proving to be highly immunogenic⁸. However, difficulties have been encountered with some HBcAg fusions expressed in *E. coli*. In particular, the FMDV-fusion could not be expressed due to its toxicity to the host cell. Consequently, this protein was expressed from vaccinia virus, a system not designed for high-level protein yield⁷. A further problem associated with occasional HBcAg fusion proteins when expressed in *E. coli* has been their sequestration as insoluble inclusion bodies⁹. Here we describe the efficient expression in yeast of the FMDV-fusion protein, and of a fusion to a peptide derived from human chorionic gonadotrophin (hCG) β -subunit⁹, which was insoluble when produced in *E. coli*.

RESULTS

Construction of yeast expression vectors for HBcAg and fusion proteins. We used the vector pWYG7, containing the galactose-regulated *GAL7* promoter, to produce HBcAg and the fusion proteins (Fig. 1). pWYG7 is derived from pJDB219, which contains the entire yeast 2 μ plasmid¹⁰, modified to contain a kanamycin-resistance marker from pUC4K¹¹. The *GAL7* promoter consists of 260bp of synthesised DNA, which is sufficient to confer full promoter activity¹², with an engineered BamHI site, at –40 relative to the ATG codon, upstream of the normal mRNA initiation site. The 5' ends of foreign genes are linked into the BamHI site using oligonucleotides, which re-create a native *GAL7* leader upstream of the ATG. The 3' ends are ligated to the BclI site of 2 μ , just upstream of the *FLP* transcriptional terminator¹³. Yeast cells containing pWYG7 or its derivatives can be selected using either G418 resistance or leucine prototrophy. In host cells that are free of native 2 μ plasmid (2 μ ^o) the plasmids are extremely stable and will probably not require continued selection on fermenter scale-up. The use of a tightly regulated promoter such as *GAL7* is essential for this stability when expressing foreign genes whose products show any degree of toxicity.

The vaccinia expression vector for FMDV-HBcAg, pvFOHC⁷ was used as a source of HBcAg DNA in all

of the FMDV-fusion (Fig. 2D) shows that all the HBcAg-reacting material sedimented near the A_{260} peak (80S ribosomes) indicating full assembly into core particles. Analysis using anti-FMDV peptide serum indicated that all the FMDV-reacting material in gradients co-sedimented with the HBcAg-reacting material (data not shown). A similar analysis showed that the hCG-fusion was also fully assembled. Though the core particles migrate near the ribosome peak, it has been possible to prepare particles of several fusion proteins of greater than 80% purity using a single sucrose gradient purification step (eg hCG-cores, Fig. 2C). However, the FMDV-cores could not be purified to this level (Fig. 2C) using sucrose gradients since there were losses due to aggregation. Epitope presentation on the surface of the FMDV- and hCG-cores was examined by electron immunocytochemistry using colloidal gold probes and the relevant specific antibody. Chimaeric cores bound colloidal gold in the presence of specific antibody (Fig. 3); controls using antibodies of unrelated specificity were negative.

In vitro analysis of FMDV-core preparations. The FMDV-cores were further tested to determine whether the VP1 142–160 peptide was intact. Some of the FMDV-cores, previously produced using the vaccinia virus expression system, had shown cleavage at the amino terminus of the epitope followed by loss of immunogenicity. This may be related to the known proteolytic susceptibility of this peptide in the intact FMD virion¹⁴.

Dilutions of two FMDV-core preparations (A1 and A2) were analysed for HBcAg and FMDV peptide using a double antibody sandwich ELISA. Results showed (Table 1) that the preparations contained equivalent activity against HBcAg and FMDV 142–160 peptide, suggesting that the peptide was present on all HBcAg particles. Furthermore, an anti-peptide MAb, produced to an FMDV 137–162 peptide/B galactosidase fusion protein¹⁵ also reacted to a similar degree with the FMDV-core preparations. Since this MAb recognises a 142–160 synthetic peptide but not 143–160 or other synthetic peptides shortened at their amino termini¹⁶, it appears that the FMDV peptide epitope on FMDV-cores is intact.

Immune response of guinea-pigs to FMDV-cores. Anti-HBcAg, anti-FMDV 142–160 peptide and FMDV neutralizing antibody titres elicited in guinea pigs following inoculation with FMDV-cores are given in Table 2. High levels of anti-HBcAg ($3.7 \log_{10}$) and anti-FMDV peptide ($2.4 \log_{10}$) antibody appeared within 14 days and these continued to rise up to 56 days, when a second inoculation was given. In the presence of very high anti-HBcAg antibody levels (greater than $5.0 \log_{10}$) the second inoculation had little or no booster effect. However, antibody levels did persist at high levels for the following 28 days, at which time the experiment was terminated. The significant levels of anti-FMDV peptide antibody were reflected in virus neutralizing activity, which appeared at 14 days and increased to protective levels in all four animals (2.2 – $2.7 \log_{10} \text{SN}_{50}$) at 56 days¹⁷. These results with an inoculum containing only $0.65 \mu\text{g}$ of FMDV peptide ($6.5 \mu\text{g}$ of FMDV-cores) confirm that the yeast-derived material has the same marked immunogenicity as the material made using a vaccinia virus expression system.

DISCUSSION

We have described the efficient production in a yeast expression system of chimaeric hepatitis B core particles carrying foreign epitopes. The two examples given here are of cores that could not be expressed in a soluble form in *E. coli* yet were expressed efficiently in yeast as soluble




FIGURE 2 Analysis of HBcAg and fusion proteins. (A) Coomassie blue-stained 12.5% SDS-polyacrylamide gel of soluble extracts from induced cells containing pWYG7HBF (track 1), no plasmid (track 2) or pWYG7HBC (track 3). (B) Western blot of similar gel to (A) probed with rabbit anti-HBcAg serum as first antibody. Tracks 1, 2, 3, 4 contained soluble proteins from induced cells containing no plasmids, pWYG7HBC, pWYG7HBF and pWYG7HBC, respectively. (C) Coomassie blue-stained gel of sucrose-gradient purified preparations of FMDV-cores (track 1) or hCG-cores (track 2). (D) Sucrose density gradient centrifugation of soluble yeast extract containing FMDV-cores. Fractions were analysed for HBcAg using ELISA.

TABLE 1 ELISA analysis of FMDV-core samples.

Fusion protein sample	Test antiserum		
	Anti-HBcAg	Anti-FMDV 142-160 peptide	Anti-FMDV/B gal fusion protein mAb
A1	1.77*	1.97	1.85
A2	2.24	2.26	2.26

* \log_{10} 50% ELISA

TABLE 2 Immune response of guinea pigs to FMDV-cores.

Antibody activity	Days post primary inoculation						
	0	14	28	56	63	70	84
Anti-HBcAg	1.0*	3.7	4.6	5.1	4.9	5.3	5.5
Anti-FMDV peptide	1.0*	2.4	3.3	3.8	3.9	3.9	3.7
FMDV neutralization	0.6**	1.1	1.5	2.5	2.5	2.7	2.7

†—second inoculation

*—mean \log_{10} ELISA endpoint titre

**—mean $\log_{10} \text{SN}_{50}$ vs 100TCID_{50} of virus




FIGURE 3 Electron micrographs of HBcAg particles (A), FMDV cores (B), and hCG-cores (C) labelled with anti-HBcAg serum (A) or the appropriate anti-peptide serum (B and C). Presence of the foreign epitope on the surface of the cores is demonstrated by antibody binding and immunogold labelling.

proteins. The expression levels obtained, 2% of soluble protein for FMDV-cores and 6–10% for hCG-cores, are equivalent to 60 mg/l and 200–300 mg/l in shake-flasks, respectively. In high-density fermentations, 10 to 20-fold shake-flask density, these figures should yield gram per litre levels.

The levels of native HBcAg produced using our *GAL7* expression vector, 6–10% of cell protein, are comparable to those of Imamura et al.¹⁸ but significantly lower than the 40% level reported by Kniskern et al.¹⁹. These authors used the constitutive *GAPDH* promoter, which is more active than *GAL7*. The *GAL7* promoter is also known to be limited in multi-copy vectors by a shortage of transcriptional activators, including *GAL4* protein²⁰. Against these disadvantages, *GAL7* is tightly regulated, an advantage in vector stability where the foreign protein has any toxicity. We are currently examining alternative promoters to see if we can increase expression levels.

The high level of expression of HBcAg is probably partly due to its stability in the yeast cell¹⁹. Superoxide dismutase (SOD) is another protein that accumulates to very high levels due to its stability²¹. Since SOD fusion proteins are also stable they have been used for the efficient production of a number of foreign proteins.

Where a mature protein is required, the SOD fusion can be cleaved at a specific site (e.g., in a proinsulin-SOD fusion²²). A similar approach has been used in fusions to the yeast transposon Ty virus-like particles (VLPs), for example in the production of HIV TAT protein²³. The hybrid VLPs, containing a factor Xa cleavage site, are readily purified by sucrose gradient centrifugation, and the mature TAT protein is released using factor Xa. Chimaeric HBcAg particles may also prove to be useful in this way, since we have found that, in general, expression levels in yeast remain high with fusion proteins. This is so even in the case of a much larger fusion, containing a 25kD immunogenic repeat region of *Plasmodium falciparum* circumsporozoite antigen (KMB and M. Lockyer, unpublished).

The FMDV-cores were expressed at a rather lower level than HBcAg, 2% of cell protein. This is not due to less efficient transcription since the FMDV-core transcript is present in yeast cells at the same high levels as that of HBcAg or other fusions (not shown). In *E. coli* the FMDV-fusion was toxic, though no toxicity was detected upon induction of yeast cells. We were only able to recover a proportion of the FMDV-cores since they appeared to aggregate during purification. However, we believe it should be possible to use alternative purification methods to prevent aggregation, since the FMDV-cores are initially fully soluble in the yeast cell lysate. The fact that the immunogenicity of FMDV-cores has been shown to approach that of the virus itself makes them a realistic proposition as a subunit vaccine for FMD. Previously the major limitation had been the low yield of the chimaeric particles produced using a vaccinia virus expression system, but we have shown here that large amounts can be produced in yeast.

Problems associated with the current FMD vaccine include, firstly, antigenic variation of the virus²⁴, secondly, the requirement of a cold chain for administration of over 2 billion vaccine doses annually, and thirdly, outbreaks of disease associated with incomplete inactivation of virus in vaccines. Our recent data suggest that freeze-dried FMDV-cores are stable at room temperature (B.E.C., unpublished) and, obviously, there is no risk of viral infection from a yeast-derived subunit vaccine. Furthermore, recent work shows that equivalent synthetic FMDV peptides for each of the seven serotypes all give rise to neutralising antibodies²⁵. Using the simple cassette replacement system described here it should be relatively straightforward to produce in yeast FMDV-cores for each serotype. A mixture of these cores could have potential as a broad-spectrum FMD vaccine.

The other epitope discussed here, from the carboxy terminus of the β -chain of hCG, is currently being examined in the development of a human contraceptive vaccine⁹. This region of hCG elicits antibodies, effective in blocking pregnancy, which do not cross-react with other hormones. Previous studies have used synthetic peptides from this region coupled to a variety of macromolecules as carriers, of which the most effective that would be acceptable for human use were tetanus and diphtheria toxin. We have recently shown that the immune response against several peptides is more efficient when the peptides are presented on HBcAg particles than when chemically coupled to other carriers²⁶. Furthermore, it has been possible to induce immune responses against HBcAg fusions in the complete absence of adjuvant²⁶.

One general limitation to all peptide and carrier immunogens is that, although high levels of neutralising antibodies may be induced, the memory helper T-cells required for an optimal anamnestic response will be carrier-specific rather than epitope- or pathogen-specific.

Therefore the use of this type of immunogen as a vaccine may be restricted to cases where pre-existing antibody levels alone confer protection against the pathogen or cases where immunity is required for a limited period²⁷. Both the FMDV and hCG examples fall into these categories.

Recently, Argos and Fuller²⁸ modelled the three-dimensional structure of HBcAg on the known X-ray crystallographic structure of the homologous Mengovirus capsid protein VP3. Neither the amino nor carboxy terminus of the polypeptide was on the external surface of the protein in this model. Therefore, if the model is correct, a certain amount of distortion would have to occur to accommodate a peptide extension on the surface. Our results of antibody binding and immunogold labelling of FMDV- and hCG-cores demonstrate the presence of the peptide extension on the particle surface (Fig. 3). Surprisingly, carboxy terminal extensions have also been made, to HBcAg, without disrupting particle assembly, and the added peptides are also external to the particle²⁹. It is difficult to compare the immunogenicity of the carboxy terminal to amino terminal fusions since immunisations with the former were carried out using multiple injections with Freund's complete adjuvant. However, it has been shown recently that particulate HBcAg is considerably less immunogenic than HBcAg, HBcAg cores being purely T-cell dependent antigens³⁰.

EXPERIMENTAL PROTOCOL

Construction of plasmids. The structure of pWYG7 and its derivatives is described in Results. Oligonucleotides for the constructions were synthesised on a Pharmacia Gene Assembler and purified by electrophoresis on a denaturing polyacrylamide gel. Their 5' ends were phosphorylated before ligation. Ligated products were introduced into *E. coli* strain MC1061³¹. The sequences of cloned synthesised regions were confirmed using the chain termination method in M13³².

Yeast transformation and induction. The expression vectors were introduced into a 2 μ version of the *Saccharomyces cerevisiae* strain S150-2B (a *leu2 his3 ura3 trp1*)³³ using the lithium transformation procedure³⁴. Transformed yeast cells were incubated in YPD broth³⁵ at 30°C overnight prior to plating on selective medium (YP + 2% glycerol + 500 μ g/ml G418), in order to increase transformation frequencies. G418 resistant colonies were screened for the *Leu*⁺ phenotype before expression analysis. For induction, transformants were grown to the mid-exponential phase (10⁷ cells/ml) in YP + 2% raffinose + 500 μ g/ml G418 at 30°C. 2% galactose was added and the culture shaken at 30°C for a further 18–24 h. The cells were then harvested by low-speed centrifugation, washed once in water and resuspended in ice-cold break buffer (20 mM sodium phosphate, pH 7.0, 0.1% Triton X-100, 4 mM PMSF, 4 mM EGTA, and 2 μ g/ml each of pepstatin, antipain, leupeptin and chymostatin; 5 ml for a 250 ml culture). Acid-washed glass beads (0.45 mm) were added and the cells broken by vortexing. The crude cell lysate was cleared by centrifugation at 10,000 g for 15 min and the protein concentration determined using the Bio-Rad protein assay.

Protein analysis. Proteins were separated in SDS-polyacrylamide gels³⁶ and stained with Coomassie blue or transferred to nitrocellulose filters for immunological detection. Stained gels were scanned using a Joyce-Loebl Chromoscan 3. Western blots were developed using horse-radish peroxidase-conjugated second antibody and 4-chloronaphthol colour reagent. In order to test for particle formation, cell extracts were layered over 15–45% w/v sucrose density gradients in phosphate-buffered saline and centrifuged in a Beckman SW28 rotor for 4 h at 28,000 rpm. The gradient was fractionated and the fractions analysed by ELISA or dot blotting.

Immunonegative stain technique. Core particles were dried onto electron microscope grids and immuno-labelled by sequential incubation with specific antibody diluted with phosphate-buffered (0.01M) saline (0.15M) pH 7.2 containing 1% BSA and either protein A-gold probes, or goat anti-mouse IgG-gold probes (each 10 nm gold spheres; Janssen Biotech, Belgium). After washing with water, the cores were negatively stained with phosphotungstate and examined in a Philips 300 transmission electron microscope.

Enzyme linked immunosorbent assay (ELISA). Modifications of the indirect and double antibody sandwich ELISA techniques described by Voller et al.³⁷ were used for antigen and antibody assays.

Antigen assay. Microplates were coated overnight at +4°C with rabbit anti-HBcAg IgG. After washing, 0.5 log₁₀ dilutions of FMDV peptide/HBcAg fusion protein were added and the plates incubated for 1 hr at 37°C. Plates were then washed and guinea pig anti-HBcAg or guinea pig anti-FMDV peptide 142–160 or mouse monoclonal antibody (MAb) against the FMDV peptide at predetermined fixed dilutions was added. After a further incubation for 1 hr at 37°C, plates were washed and anti-guinea-pig or anti-mouse IgG-peroxidase conjugates was added. After a final incubation for 1 hr at 37°C the plates were washed and an enzyme substrate (0.04% o-phenylenediamine + 0.004% hydrogen peroxide in phosphate/citrate buffer) was added. The resulting colour development was stopped with 12.5% sulphuric acid after a few minutes and the absorbance at 492 nm was measured in a Titertek Multiskan (Flow Laboratories, Irvine, Ayrshire). The A₄₉₂ values obtained were plotted against the log₁₀ reciprocal fusion protein dilution and a 50% endpoint titre was calculated by reference to minimum and maximum A₄₉₂ values.

Antibody assay. Microplates were coated overnight at +4°C with bacterially expressed HBcAg or synthetic FMDV peptide 141–160. Plates were washed and test guinea pig serum samples at 0.5 log₁₀ dilutions from 1:10 were added. After incubation for 1 hr at 37°C, plates were washed and anti-guinea pig IgG-peroxidase conjugate was added. After a further hour at 37°C plates were developed with substrate solution as described above. The A₄₉₂ values obtained were plotted against the log₁₀ reciprocal antiserum dilution and the antibody endpoint titres were calculated by reference to a negative standard (a 1:10 dilution of pre-inoculation guinea pig serum).

Neutralization assay. The FMDV neutralizing activity of serum samples against 100 TCID₅₀ of virus was determined using a micro neutralization test with IBRS-2 cells³⁸. Each test was performed in duplicate and the results were recorded as the mean log₁₀ reciprocal of the serum dilution that gave confluent cell sheets in 50% of the microplate wells (SN₅₀).

Animals. Four female Dunkin-Hartley guinea pigs weighing approximately 450g were inoculated intramuscularly with a 6.5 μ g dose of HBcAg fusion protein, containing 0.65 μ g of FMDV peptide sequence, formulated in incomplete Freund's adjuvant (IFA). All animals were boosted with a similar inoculum at 56 days. Serum samples, collected at 7 to 14 day intervals, were stored at -20°C prior to analysis for antibody activity.

Acknowledgments

We wish to thank A. Syred for peptide synthesis; Gillian Z Hastings for technical assistance; Betty Enger-Valk and M. K. Kotrenhagan from TNO Laboratories, The Netherlands, for the anti-FMDV peptide monoclonal antibody; Tony Carroll and Dave Rowlands for helpful discussions; and Tina Silva for typing the manuscript.


Received 18 January 1990; accepted 21 March 1990.

References

1. Stahl, S., Mackay, P., Agazin, M., Bruce, S. A. and Murray, K. 1989. Hepatitis B virus core antigen: synthesis in *Escherichia coli* and application in diagnosis. *Proc. Natl. Acad. Sci. USA* **79**:1606–1610.
2. Miyahara, A., Imamura, T., Araki, M., Sugawara, K., Ohtomo, N. and Matsubara, K. 1986. Expression of hepatitis B virus core antigen gene in *Saccharomyces cerevisiae*: synthesis of two polypeptides translated from different initiation codons. *J. Virol.* **59**:176–180.
3. Jean-Jean, O., Levrero, M., Will, H., Pericaudet, M. and Rossignol, J.-M. 1989. Expression mechanism of the Hepatitis B virus (HBV) C gene and biosynthesis of HBc antigen. *Virology* **170**:99–106.
4. Milich, D. R. and McLachlan, A. 1986. The nucleocapsid of the hepatitis B virus is both a T-cell independent and a T-cell dependent antigen. *Science* **234**:1398–1401.
5. Valenzuela, P., Coit, D., Medina-Selby, M. A., Kuo, C. H., Van Nest, G., Burke, R. L., Bull, P., Urdea, M. S. and Graves, P. V. 1985. Antigen engineering in yeast: synthesis and assembly of hybrid hepatitis B surface antigen herpes simplex Ig D particles. *BioTechnology* **3**:323–326.
6. Adams, S. E., Dawson, K. M., Gull, K., Kingsman, S. M. and Kingsman, A. J. 1987. The expression of hybrid HIV-Ty virus-like particles in yeast. *Nature* **329**:68–70.
7. Clarke, B. E., Newton, S. E., Carroll, A. R., Francis, M. J., Appleyard, G., Syred, A. D., Highfield, P. E., Rowlands, D. J. and Brown, F. 1987. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. *Nature* **330**:381–384.
8. Clarke, B. E., Brown, A. L., Grace, K. G., Hastings, G. Z., Brown, F., Rowlands, D. J. and Francis, M. J. 1990. Presentation and immunoge-

- nicity of viral epitopes on the surface of hybrid hepatitis B virus core particles produced in bacteria. *J. Gen. Virol. In press.*
9. Stevens, V. C. 1986. A synthetic peptide vaccine against human chorionic gonadotrophin. *Vaccines* 86. Cold Spring Harbor Laboratory, N.Y.
 10. Beggs, J. D. 1978. Transformation of yeast by a replicating hybrid plasmid. *Nature* 275:104-109.
 11. Vieira, J. and Messing, J. 1982. The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers. *Gene* 19:259-268.
 12. Tajima, M., Nogi, Y. and Fukasawa, T. 1985. Primary structure of the *Saccharomyces cerevisiae* GAL7 gene. *Yeast* 1:67-77.
 13. Sutton, A. and Broach, J. R. 1985. Signals for transcription initiation and termination in the *Saccharomyces cerevisiae* plasmid 2µm circle. *Mol. Cell. Biol.* 5:2770-2780.
 14. Strohmaier, K., Franze, R. and Adam, K.-H. 1982. Location and characterisation of the antigenic portion of the FMDV immunising protein. *J. Gen. Virol.* 59:295-306.
 15. Broekhuijsen, M. P., Van Rijn, J. M. M., Blom, A. J. M., Pouweis, P. H., Enger-Volk, B. E., Brown, F. and Francis, M. J. 1987. Fusion proteins with multiple copies of the major determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals. *J. Gen. Virol.* 68:3137-3143.
 16. Parry, N. R., Ouldrige, E. J., Burnett, P. V., Clarke, B. E., Francis, M. J., Fox, J. D., Rowlands, D. J. and Brown, F. 1989. Serological prospects for peptide vaccines against food-and-mouth disease virus. *J. Gen. Virol.* 70: *In press.*
 17. Francis, M. J., Fry, C. M., Rowlands, D. J. and Brown, F. 1988. Qualitative and quantitative differences in the immune response to foot-and-mouth disease virus antigens and synthetic peptides. *J. Gen. Virol.* 69:2483-2491.
 18. Imamura, T., Sugahara, K., Adachi, S., Miyatsu, Y., Mizokami, H. and Matsusaka, T. 1988. Purification and characterisation of the hepatitis B virus core antigen produced in the yeast *Saccharomyces cerevisiae*. *J. Biotechnol.* 8:149-162.
 19. Kniskern, P. J., Hagopian, A., Montgomery, D. L., Burke, P., Dunn, N. R., Hofmann, K. J., Miller, W. J. and Ellis, R. W. 1986. Unusually high-level expression of a foreign gene (hepatitis B core antigen) in *Saccharomyces cerevisiae*. *Gene* 46:135-141.
 20. Baker, S. M., Johnston, S. A., Hopper, J. E. and Jaehning, J. A. 1987. Transcription of multiple copies of the yeast GAL7 gene is limited by specific factors in addition to GAL4. *Mol. Gen. Genet.* 208:127-134.
 21. Hallewell, R. A., Mills, R., Tekamp-Olson, P., Blacher, R., Rosenberg, S., Otting, F., Masairz, F. R. and Scandella, C. S. 1987. Amino terminal acetylation of authentic human Cu, Zn superoxide dismutase. *BioTechnology* 5:363-366.
 22. Cousens, L. S., Shuster, J. R., Gallegos, C., Ku, L., Stampien, M. M., Urdea, M. S., Sanchez-Pescador, R., Taylor, A., Tekamp-Olson, P. 1987. High level expression of proinsulin in the yeast, *Saccharomyces cerevisiae*. *Gene* 61:265-275.
 23. Braddock, M., Chambers, A., Wilson, W., Esnouf, M. P., Adams, S. E., Kingsman, A. J. and Kingsman, S. M. 1989. HIV-1 TAT activates presynthesised RNA in the nucleus. *Cell* 58:269-279.
 24. Pereira, H. G. 1978. Antigenic variation in relation to epidemiology and control of foot-and-mouth disease. *Brit. Vet. J.* 134:58-62.
 25. Francis, M. J., Hastings, G. Z., Clarke, B. E., Brown, A. L., Beddell, C. R., Rowlands, D. J. and Brown, F. 1990. Neutralising antibodies to all seven serotypes of foot and mouth disease virus elicited by synthetic peptides. *Immunology* 69:171-176.
 26. Francis, M. J., Clarke, B. E., Hastings, G. Z., Brown, A. L., Rowlands, D. J. and Brown, F. 1990. Immune response to peptide/hepatitis B core antigen fusion proteins. *Vaccines '90*, Cold Spring Harbor Laboratory, N.Y. *In press.*
 27. Zanetti, M., Sercarz, E. and Salk, J. 1987. The immunology of new generation vaccines. *Immunology Today* 8:18-25.
 28. Argos, P. and Fuller, S. D. 1988. A model for hepatitis B virus core protein: prediction of antigenic sites and relationship to RNA virus capsid proteins. *EMBO J* 7:819-824.
 29. Stahl, S. J. and Murray, K. 1989. Immunogenicity of peptide fusions to Hepatitis B virus core antigen. *Proc. Nat. Acad. Sci.* 86:6283-6287.
 30. Milich, D. R., McLachlan, A., Stahl, S., Wingfield, P., Thornton, G. B., Hughes, J. L. and Jones, J. E. 1988. Comparative immunogenicity of hepatitis B virus core and e antigens. *J. Immunol.* 141:3617-3624.
 31. Casadaban, M. and Cohen, S. 1980. Analysis of gene control signals by DNA fusion and cloning in *Escherichia coli*. *J. Mol. Biol.* 138:179-207.
 32. Sanger, F., Coulson, A. R., Barrell, B. G., Smith, A. J. H. and Roe, B. A. 1980. Cloning in single-stranded bacteriophage as an aid to rapid DNA sequencing. *J. Mol. Biol.* 143:161-178.
 33. McLeod, M., Volkert, F. and Broach, J. 1984. Components of the site-specific recombination system encoded by the yeast plasmid 2-micron circle. *Cold Spring Harbor. Quant. Symp. Biol.* 49:779-787.
 34. Ito, H., Fukuda, Y., Murata, K. and Kimura, A. 1983. Transformation of intact yeast cell treated with alkali cations. *J. Bact.* 153:163-168.
 35. Sherman, F., Fink, G. R. and Lawrence, C. W. 1983. *Methods in Yeast Genetics*. Cold Spring Harbor, N.Y.
 36. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227:680-685.
 37. Voller, A., Bartlett, A., Blunell, D. E., Clark, M. F. and Adams, A. N. 1976. The detection of virus by enzyme-linked immunosorbent assay (ELISA). *J. Gen. Virol.* 33:165-167.
 38. Francis, M. J. and Black, L. 1983. Antibody response in pig nasal fluid and serum following foot-and-mouth disease infection or vaccination. *J. Hygiene* 91:329-334.

NO. 217 CRASSENT FOR PREPARATIVE



READ FAST GELS READY TO GO

200 HARRIS ST. PYRMONT 2009 AUSTRALIA
TEL (02) 692 9999 FAX (02) 692 8459

Accurate Chemical & Scientific Corporation
 10000 WILSON BLVD, SUITE 100, WILSON, CA 94094
 TEL (415) 947-0000 FAX (415) 947-0001

Gerhard Frobel Laborstechnik
 10000 WILSON BLVD, SUITE 100, WILSON, CA 94094
 TEL (415) 947-0000 FAX (415) 947-0001

Rowgen Instruments Ltd
 10000 WILSON BLVD, SUITE 100, WILSON, CA 94094
 TEL (415) 947-0000 FAX (415) 947-0001

Write in No. 217 on Reader Service Card